To summarize, on one hand the modest upwards trajectory of the obese and diabetic population provides a fertile ground for Pharma companies to sell more for the years to come, however, downside risks remain, including: pricing, compounders and overall competition, which will make it hard for companies like Novo and Lilly to maintain their growth
Who qualifies for the program
Just under 10 percent are categorized as severely obese, a group that has been growing quickly across the country
for selling eyedrops with gross microbial growth that could lead to life-threatening infections, and for failing to investigate complaints about contaminated products
On the other hand, miRNA-17-5p lipoplex and miR1455p agomir given to mice are found to increase inflammatory cytokine levels (MMP3, MMP9, MMP13), aggravating arthritis in the future (212, 236)
September 26 Product: AstraZenecas Tagrisso Indication : Non-small cell lung cancer AstraZeneca expanded the reach of its non-small cell lung cancer (NSCLC) drug Tagrisso Thursday as the FDA greenlit the treatment for adults with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) disease that has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy